T. Rowe Price Associates
NAMS icon

T. Rowe Price Associates’s NewAmsterdam Pharma NAMS Stock Holding History

T. Rowe Price Associates’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.6M Buy
+1,167,357
New +$38.5M ﹤0.01% 959
2026
Q1 		– Sell
-116,258
Closed -$4.08M – 3175
2025
Q4 		$4.08M Sell
116,258
-22,071
-16% -$803K ﹤0.01% 1468
2025
Q3 		$3.94M Buy
+138,329
New +$3.32M ﹤0.01% 1468

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

T. Rowe Price Associates's NAMS Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 1,167,357 shares worth $39.6M. The stake represents ﹤0.01% of the portfolio and ranks #959 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in NAMS as recently as Q4 2025.

T. Rowe Price Associates first reported a position in NAMS in Q3 2025 and has held it in 3 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • T. Rowe Price Associates held 1,167,357 shares of NewAmsterdam Pharma worth $39.6M as of Q2 2026.
  • NewAmsterdam Pharma was a new T. Rowe Price Associates position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #959 holding.
  • T. Rowe Price Associates first reported a position in NewAmsterdam Pharma in Q3 2025 and has held it in 3 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.